This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This week, were celebrating a significant milestone: the release of our 200th episode of the Xtalks LifeScience Podcast ! We’re excited to continue our journey by bringing you more in-depth conversations with industry leaders, highlighting the innovations and trends that shape the future of lifesciences.
Lifescience podcasts have emerged as an invaluable tool for building connections with audiences in the digital era. Furthermore, we’ll explore the unique advertising opportunities that this platform offers, positioning brands at the forefront of the lifescience industry. The result?
As pharmaceutical marketers prepare their brands for the future, there are a number of important ways they can learn from digitally-native brands. Analysing the world of digitally-native brands highlights three standout ways in which parts of their approach could be brought to the pharmaceutical world. Be more agile .
ODAIA, a lifesciences predictive analytics and commercial insights provider, has secured an investment of $25m in its Series B funding round. This software-as-a-service (SaaS) platform is also used by lifesciencebrands to launch their drugs, therapeutics and vaccines in the markets, using data-driven solution.
on National Health Service (NHS) sales of branded medicines in 2023, almost double that of the previous year, has sent shock waves through the pharma industry. The forecast branded NHS drug sales growth figure for 2023 was adjusted to 5.63%. The UK government’s decision to set an unprecedented payback rate of 26.5% billion ($4.1
In 2023, there were significant advancements and notable trends in the lifesciences. Xtalks compiled a list of its top lifescience news and trends of 2023, which provided readers with the latest developments, information and expert insights across lifescience industries, including pharma, biotech and medical device.
The US Food and Drug Administration (FDA) has given emergency use authorization (EUA) to Novavax’s COVID-19 vaccine, making it the fourth authorized vaccine in the US against COVID-19. The vaccine is branded as Nuvaxovid outside the US with approvals/authorizations in Canada, the EU, UK, Australia and South Korea.
16th Annual LifeSciences Trade and Channel Strategies. That’s why the lifescience industry’s top experts will come together virtually on December 1-3 at Trade and Channel 2020. December 1-3, 2020 | Virtual Event www.informaconnect.com/trade-channel.
16th Annual LifeSciences Trade and Channel Strategies. December 1-3, 2020 | Virtual Event www.informaconnect.com/trade-channel. Get ready to hit the ground running in 2021 by closing out the year at Trade and Channel 2020 !
Trust in lifescience companies has fluctuated since the start of the pandemic. The reputation of COVID-19 vaccine makers understandably soared early on, as clinical trials were started and completed in record time, giving hopes to millions of people in lockdown. Choose something that relates to your brand(s) or team.
Any authorization for drugs, vaccines, and medical devices issued pursuant to the interim orders are also set to terminate when the respective interim order expires or is withdrawn. Drugs and Vaccines. Both interim orders are set to expire 1 year after they were issued, or sooner if withdrawn by the Minister.
The past two years have shone a spotlight on the UK lifesciences industry. The UK pharma sector should emerge from COVID-19 with a great deal of goodwill in the bank, especially after rapidly developing vaccines that are helping to steer the world out of the pandemic. A reputational problem remains. About the author.
Dr. B was founded in 2021 to connect providers with leftover COVID vaccines to the patients seeking to receive them. Though it’s not an online pharmacy that fills patients’ medication, it’s looking to offer a way for patients to easily compare drug prices in the future, including listing name-brand drugs against generic versions.
Yesterday morning, we held the official grand opening of our brand-new Hudson Yards location, an office tower located at 66 Hudson Boulevard (The Spiral) at Hudson Yards of Manhattan, complete with a ribbon-cutting to officially open the facility.
This was, and still is being, demonstrated through the UK’s COVID-19 vaccine research successes. He combines his experience in mobile and technology startups, with 5 years at Google where he held the roles of UK head of mobile and UK head of brand solutions, to achieve this goal.
In October 2022, Xtalks celebrated two decades of bringing diverse stakeholders in the lifescience industry together through first holding physical events, then soon after, hosting exclusively online events. Pfizer is also the co-developer of what is arguably the most successful COVID-19 vaccine rollout.
New survey data from Press Ganey suggests that pharma may be able to get an edge by integrating physician directories into brand websites. By embedding a provider directory in the company’s website or brand websites. Now it’s vaccines for COVID, innovation, lives being saved, sort of this Herculean effort to combat the pandemic.
The company’s new brand identity includes a new website, curiaglobal.com , that features the tagline, “From curiosity to cure” that plays on the Curia name. Related: AMRI Signs Supply Agreement with AstraZeneca to Manufacture COVID-19 Vaccine. Curia’s brand colors include the pairing of a bright purple/plum with yellow.
In the commercial, Pfizer highlighted some of its major scientific offerings throughout the centuries, which include contributions to the mass production of penicillin and creating COVID-19 vaccines. In 2023, alone, the company said its medicines and vaccines reached more than 1.3
However, according to Jennifer Turcotte, pharma advisor in the company’s healthcare and lifesciences division, there was also some good news. Traditionally, pharma has tried to build relationships at the brand-level,” said Scott Bradley, cross-portfolio vice president of patient and speciality services at Novartis. “We
State Premier of North Rhine-Westphalia Armin Laschet and Birgitta Radermacher, President of Duesseldorf Administrative District, today visited Bayer AG’s research and production site in Wuppertal to gain an insight into the planned vaccine production there. Effective vaccines are our best weapon to combat the pandemic. About Bayer.
Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac’s COVID-19 vaccine candidate CVnCoV. “The need for vaccines against COVID-19 is enormous. “We are highly committed to making our capabilities and networks available to help end this pandemic.”
He also had to renegotiate a contract with GSK relating to ofatumumab – branded at that time as Arzerra. But he is also inspired by the rapid response and progress made by the lifesciences and pharma to combat the pandemic. “It Clinical trials are slower to run and complete because hospitals are busy with COVID-19 cases.
The online event also heard from Pfizer and patient advocate representatives and looked at how the NIHR’s collective approach allows lifesciences firms to engage with patients while remaining aligned with ethics guidelines and codes of conduct – providing a UK solution to a global problem.
The name Zeneca was invented by a branding consultancy who had been instructed to find a name which was memorable, had no associations with other companies, nor was offensive in any language”. In June 2007, AstraZeneca completed the acquisition of vaccine maker MedImmune, buying its drug-development pipeline for $15.2
How will running webinars in 2022 develop my brand’s unique value in the market? Read more on why webinars are an important tool for brand development here. How to leverage the experiences we have gained during the COVID-19 pandemic to address the need for accelerating pediatric medicines and vaccines development .
The role of the generics sector has also been able to complement the outputs from innovator companies in the development of COVID-19 vaccines and shows the crucial significance of working together to provide joint solutions to this exceptional global emergency. Ensuring healthcare sustainability.
AstraZeneca has unveiled plans to build a brand new manufacturing facility at a site in Ireland operated by its recent acquisition Alexion, providing employment for around 100 workers including scientists and engineers. “This significant investment will ensure the AstraZeneca supply network is fit for the future.”
BioRad Laboratories Lifescience research and diagnostics giant BioRad announced a 5% workforce reduction over 350 employees with the most significant cuts at its Hercules headquarters, along with additional layoffs at its Pleasanton and Richmond locations. At the J.P.
Marie-Anne has had a successful 30+ year international career spanning the consumer and luxury sectors, growing businesses, and shaping brands through innovation and creativity. Most recently, Marie-Anne led the worldwide Oral Care category at Unilever PLC where she developed a portfolio of new premium brands. Source link: [link].
They include proteins, monoclonal antibodies and vaccines that are considered to be “ highly similar ” to biological products that have already been approved by the FDA. Like generic forms of synthetic pharmaceuticals, biosimilars have the advantage of being less costly compared to their branded counterparts. What is a Biosimilar?
Will all the efforts to speed up market access and ensure that the UK remains attractive to the lifesciences industry post-Brexit pay off in 2022? VPAS essentially balances access with scheme members guaranteeing that NHS spend on branded medicines won’t grow by more than 2 percent a year.
Among these are Madrigal Pharmaceuticals’ resmetirom (branded Rezdiffra) , which secured FDA approval in March for the treatment of nonalcoholic steatohepatitis (NASH) and sotatercept (commercial name Winrevair) for pulmonary hypertension (PAH). The condition is an adverse event linked to competitor vaccines. percent to 77.8
After the war, Pfizer continued to focus on industrial chemicals as much as medicines, producing the citric acid needed for the emerging soft drinks industry, fuelling brands like Coca Cola and Dr Pepper’s expansion in the 1880s. By 1868, Pfizer’s revenues had doubled since the start of the war, and their product lines had expanded greatly.
Biosimilar and interchangeable products can expand treatment options and lower drug and healthcare costs by offering a cheaper alternative with the same effectiveness; essentially a non-branded version of a biologic such as monoclonal antibodies, proteins and vaccines. million in 2019, according to Fortune Business Insights.
AstraZeneca Dives into Rare Diseases: AstraZeneca has been in the spotlight for the COVID-19 vaccine candidate it developed with Oxford University. The company has a number of branded products in this space, including Soliris (eculizumab), a first-in-class anti-complement component 5 (C5) monoclonal antibody. But the U.K.-based
Speaking at the virtual Capital Markets Day on Wednesday, CEO Werner Baumann emphasized Bayer’s long-term growth perspectives: “Bayer is a leading lifescience company, uniquely positioned at the intersection of health and nutrition – with attractive prospects for growth, earnings and cash flow.” Speeding up sales growth.
This means all of the company’s over-the-counter (OTC) drugs and supplements such as pain, allergy and cold medications, and vitamins will have brand packaging that is 100 percent recyclable or reusable in less than ten years’ time. Related: Pharma Rivals Step Up to Assist with COVID-19 Vaccine Production.
In addition, creating partnerships and engaging with lifescience companies early on can be highly beneficial here, ensuring that a study is set up in the right location, with the right expertise. Jonathan believes in the power of personalised healthcare to improve and transform the health outcomes for everyone.
The Old Guidance applied only to drugs for use in humans, whereas the Distinction Guidance now applies to drugs (both prescription and non-prescription), medical devices, natural health products, biologics, vaccines, and animal health products. New examples. Definition of “general public”.
21, 2020 (GLOBE NEWSWIRE) — SELLAS LifeSciences Group, Inc. GPS has previously been shown to invoke multi-epitope, broad cross-reactivity along the full-length of the WT1 protein, suggestive of epitope spreading, and immunologically mediated cancer cell destruction, which are hallmarks of an effective cancer vaccine.
Medical science liaisons and medical affairs personnel are becoming increasingly important customer-facing components of the team, as sales rep access continues to be limited. “We’re seeing brands increase budgets for Medical Affairs,” says Stewart Young, SVP, Strategic Planning, Intouch Proto.
.: Breakthroughs that Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. is the world leader in serving science, with annual revenue over $40 billion. About Thermo Fisher Scientific Thermo Fisher Scientific Inc.
Before joining Solvias Group, Karen held various senior leadership roles at Novartis, including global head investor relations from 2000 to 2006, head M&A and Executive Committee member, as well as site head for the Vaccines & Diagnostics division between 2006 and 2011. Dr. Shamiram R.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content